AllianceRx Walgreens Pharmacy offers Lunsumio, Jaypirca
AllianceRx Walgreens Pharmacy, one of the largest specialty and home delivery pharmacies, will now distribute two medications indicated for adults with certain types of lymphoma.
Lunsumio (mosunetuzumab-axgb) is used to treat adults with follicular lymphoma whose cancer has come back or did not respond to previous treatment and who have already received two or more lines of systemic therapy for their cancer. Genentech, a member of the Roche Group, manufactures Lunsumio.
Jaypirca treats adults with mantle cell lymphoma that has come back or did not respond to previous treatment and who have already received two or more lines of systemic therapy for their cancer, including a Bruton tyrosine kinase inhibitor medicine. Eli Lilly manufactures Jaypirca.
Read more: AllianceRX Walgreens Prime to become AllianceRx Walgreens Pharmacy]
Lymphoma is a cancer that starts in the lymph system (the tissues and organs producing, storing, and carrying white blood cells fighting infections). The two main kinds of lymphoma include Hodgkin lymphoma, which spreads in an orderly manner from one group of lymph nodes to another, and non-Hodgkin lymphoma, which spreads through the lymphatic system in a non-orderly manner.
[Read more:AllianceRx Walgreens Pharmacy makes new name official]
“We are honored to be selected by these manufacturers as a specialty pharmacy provider for patients with these types of NHLs,” said Tracey James, chief operating officer at AllianceRx Walgreens Pharmacy. “Patients living with lymphoma or any cancer not only deserve access to the therapies they need, but also the support to help them throughout their treatment journey. Our Specialty360 Therapy Teams are dedicated pharmacy teams that support specific conditions and therapies and provide personalized support for patients. We share a desire with manufacturers to provide holistic patient care and optimal outcomes for patients.”